» Articles » PMID: 39715834

[Efficient Treatment of Mild Crohn's Disease and Mild Ulcerative Colitis]

Overview
Specialty General Medicine
Date 2024 Dec 23
PMID 39715834
Authors
Affiliations
Soon will be listed here.
Abstract

The cornerstone of treatment for mild ulcerative colitis is still the oral or topical (rectal) application of aminosalicylates (5-ASA). 5‑ASA preparations are often only administered orally in mild ulcerative colitis. Study data show that in ulcerative proctitis and left-sided colitis, rectal 5‑ASA preparations are even more effective than oral administration. In a next step, steroid-containing topical therapies should be used. Topical steroids such as budesonide are also primarily used in mild Crohn's disease. However, it is controversial whether treatment is necessary in symptom-free patients. There is still a lack of evidence to prove that more aggressive treatment (using immunosuppressants, biologics or small molecules) has a long-term benefit in these patients. Most guidelines are critical of the use of 5‑ASA in mild Crohn's disease. Nevertheless, there is some evidence for sufficiently high-dose treatment with 5‑ASA, although one must be aware of its limited effectiveness. However, there is clear evidence for the postoperative use of 5‑ASA in cases of mild recurrence.

References
1.
Barberio B, Segal J, Quraishi M, Black C, Savarino E, Ford A . Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis. J Crohns Colitis. 2021; 15(7):1184-1196. DOI: 10.1093/ecco-jcc/jjab010. View

2.
Bonovas S, Nikolopoulos G, Piovani D, Gonzalez-Lorenzo M, Pantavou K, Lytras T . Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis. Br J Clin Pharmacol. 2019; 85(10):2244-2254. PMC: 6783624. DOI: 10.1111/bcp.14051. View

3.
Burisch J, Katsanos K, Christodoulou D, Barros L, Magro F, Pedersen N . Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study. J Crohns Colitis. 2018; 13(2):198-208. DOI: 10.1093/ecco-jcc/jjy154. View

4.
Burisch J, Kiudelis G, Kupcinskas L, Kievit H, Andersen K, Andersen V . Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut. 2018; 68(3):423-433. DOI: 10.1136/gutjnl-2017-315568. View

5.
Coward S, Kuenzig M, Hazlewood G, Clement F, McBrien K, Holmes R . Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis: Republished. Inflamm Bowel Dis. 2018; 23(5):E26-E37. DOI: 10.1097/MIB.0000000000001158. View